Fibroblast-Facilitated Islet Engraftment for Immune Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Type 1 diabetes, such as life-long insulin therapy and islet cell transplantation, face challenges including frequent hypoglycemic episodes, invasive procedures, limited islet availability, and inadequate long-term immunosuppression, leading to graft failure and auto-immune effects.
Innovation Solution
Administration of allogeneic insulin-producing cells, CD73-positive fibroblasts, and allogeneic EPCs to stimulate a tolerogenic immune response, enhancing islet engraftment by modulating antigen-specific T and B regulatory cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If calcineurin inhibitors are used for immunosuppression to protect transplanted islets, then immune rejection is reduced, but pancreatic beta cell function and insulin sensitivity are negatively affected
Solution Approach 1:
The patent uses CD73-positive fibroblasts as intermediary cells that mediate immune tolerance through antigen-specific T regulatory cell stimulation. These fibroblasts act as a bridge between the transplanted islets and the host immune system, inducing tolerogenic responses without requiring calcineurin inhibitors that harm beta cell function.
Solution Approach 2:
The patent converts the harmful autoimmune response that typically destroys transplanted islets into a beneficial tolerogenic immune response. By using allogeneic fibroblasts to stimulate antigen-specific T regulatory cells, the previously harmful immune system becomes protective of the graft.
2Productivity
If islet cell transplantation is performed to achieve insulin independence, then diabetes treatment effectiveness is improved, but long-term engraftment stability is insufficient with only 10% graft survival at 5 years
Solution Approach 1:
The patent applies preliminary immunomodulatory action by administering CD73-positive fibroblasts before or concomitantly with islet transplantation. This preliminary action establishes a tolerogenic immune environment in advance, preventing rejection before it occurs and ensuring long-term graft survival.
Solution Approach 2:
The patent changes the immune system's response parameters from rejection to tolerance. By stimulating antigen-specific T regulatory cells through fibroblast administration, the immune response parameters are fundamentally altered to protect rather than attack the transplanted islets.
3Quantity of substance
If multiple islet donors are utilized to achieve sufficient islet availability, then transplant material quantity is improved, but procedural complexity and immune suppression requirements increase
Solution Approach 1:
The patent makes the fibroblast-based tolerogenic protocol universally applicable to islets from multiple donors. The antigen-specific T regulatory cell stimulation mechanism works across different donor islets, creating a universal immunoprotective approach that simplifies multi-donor transplantation procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Improves islet engraftment and survival by inducing a tolerogenic immune response, reducing immune rejection, and maintaining graft function, thereby stabilizing glucose control.
Implementation Method 1
stimulating in an individual a tolerogenic immune response to one or more antigens associated with insulin producing cells
Data Source
Figure 1
AI summary
Embodiments of the disclosure pertain to the treatment of diabetes through replacement of insulin producing cells. In specific embodiments, the disclosure encompasses the use of cellular adjuvants to enhance survival, engraftment and tolerogenesis of insulin-producing cells. In certain cases the disclosure concerns the manipulation of a hepatic microenvironment to promote immunological tolerance at an enhanced level to allow for integration of allogeneic insulin-producing cells. Particular embodiments utilize fibroblasts to enhance immunological tolerance for insulin-producing cells upon engraftment.